NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Now that we have seen the core data, it seems that approval would be the best path forward to further develop the technology and to maximize the benefit of DCVax-L as a platform since it is incredibly safe and has proven efficacy. Any RA holding back such a safe and effective therapy simply would not make sense. Doctors and patients using the therapy would only serve to inform its application beyond GBM and accelerate other trials that include DCVax-L or other agents. Data collection and analysis only continue after approval and approval opens up a vast new universe of possibilities.

I would think that confirming safety on balance with potential benefit are all that RAs should be doing in their role, and then they must pass the baton to the doctors in the field who take it from there. DCVax-L is certainly ready to graduate to the stage where it can be used by doctors in the field where it now belongs. After liberation from clinical trials, It will advance the science of immunotherapy and enlighten new paths forward where toxic and otherwise harsh therapies are not always the only option. Beyond extending lives, the learning and discovery that would come from its use on a larger scale would be invaluable.

If the world is right side up in this case, and day is not night, then I would expect swift movement toward approval and toward advancing the science.